

Georges Jourdi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1791317/publications.pdf>

Version: 2024-02-01

27
papers

566
citations

1039406

9
h-index

642321

23
g-index

28
all docs

28
docs citations

28
times ranked

872
citing authors

#	ARTICLE	IF	CITATIONS
1	Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 8S-28S.	0.7	114
2	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. <i>Cell Death and Disease</i> , 2021, 12, 258.	2.7	113
3	Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. <i>Angiogenesis</i> , 2021, 24, 505-517.	3.7	105
4	Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2015, 114, 78-86.	1.8	34
5	Potential usefulness of activated charcoal (DOAC remove [®]) for dRVVT testing in patients receiving Direct Oral AntiCoagulants. <i>Thrombosis Research</i> , 2019, 184, 86-91.	0.8	30
6	Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood. <i>European Journal of Anaesthesiology</i> , 2019, 36, 449-456.	0.7	22
7	Lupus Anticoagulant Single Positivity During the Acute Phase of COVID-19 Is Not Associated With Venous Thromboembolism or In-Hospital Mortality. <i>Arthritis and Rheumatology</i> , 2021, 73, 1976-1985.	2.9	21
8	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13079.	1.8	20
9	A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter. <i>Frontiers in Medicine</i> , 2021, 8, 683357.	1.2	13
10	Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 805525.	1.1	12
11	Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 738-744.	0.7	9
12	Effect of rivaroxaban and dabigatran on platelet functions: in vitro study. <i>Thrombosis Research</i> , 2019, 183, 159-162.	0.8	9
13	Prospective Evaluation of a Rapid Functional Assay for Heparin-Induced Thrombocytopenia Diagnosis in Critically Ill Patients*. <i>Critical Care Medicine</i> , 2019, 47, 353-359.	0.4	8
14	Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 93.	1.8	8
15	FXa-Î±2-Macroglobulin Complex Neutralizes Direct Oral Anticoagulants Targeting FXa In Vitro and In Vivo. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1535-1544.	1.8	7
16	Study of thrombin generation with St Genesis to evaluate xaban pharmacodynamics: Analytical performances over 18 months. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 821-830.	0.7	7
17	GFHT proposals on the practical use of argatroban — With specifics regarding vaccine-induced immune thrombotic thrombocytopenia (VITT). <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100963.	0.6	6
18	Anticoagulation therapy in France: state-of-the-art in 2020. <i>Annals of Blood</i> , 0, 5, 3-3.	0.4	5

#	ARTICLE	IF	CITATIONS
19	High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 178-186.	1.0	5
20	No impact of cancer and plague-relevant <i>FPR1</i> polymorphisms on COVID-19. <i>Oncolmmunology</i> , 2020, 9, 1857112.	2.1	4
21	Induced forms of $\hat{\pm}2$ -macroglobulin neutralize heparin and direct oral anticoagulant effects. <i>International Journal of Biological Macromolecules</i> , 2021, 184, 209-217.	3.6	4
22	Thrombin generation test: A reliable tool to evaluate the pharmacodynamics of vitamin K antagonist rodenticides in rats. <i>Pesticide Biochemistry and Physiology</i> , 2018, 146, 19-24.	1.6	3
23	Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study. <i>European Journal of Pharmacology</i> , 2021, 891, 173764.	1.7	3
24	Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. <i>Frontiers in Pharmacology</i> , 2022, 13, 878416.	1.6	2
25	Strategies of neutralization of the direct oral anticoagulants effect: review of the literature. <i>Annales De Biologie Clinique</i> , 2019, 77, 67-78.	0.2	1
26	Strategies of neutralization of the direct oral anticoagulants effect: review of the literature. <i>Hematologie</i> , 2019, 25, 233-247.	0.0	0
27	Coagulation Characterization of Prothrombin 20209Câ€™>â€™T Variant: About 27 New Cases. <i>Thrombosis and Haemostasis</i> , 2021, 121, 246-249.	1.8	0